These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1449 related articles for article (PubMed ID: 34396940)

  • 1. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study.
    Li XN; Huang Y; Wang W; Jing QL; Zhang CH; Qin PZ; Guan WJ; Gan L; Li YL; Liu WH; Dong H; Miao YT; Fan SJ; Zhang ZB; Zhang DM; Zhong NS
    Emerg Microbes Infect; 2021 Dec; 10(1):1751-1759. PubMed ID: 34396940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021.
    Ma C; Sun W; Tang T; Jia M; Liu Y; Wan Y; Han J; Rodewald L; Li J; Song Y; Wang Y; Wu D; Wang F; Zheng H; Tang L; Gao GF; Yin Z; An Z
    Vaccine; 2022 May; 40(20):2869-2874. PubMed ID: 35400561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case-control study.
    Zhang X; Wang Y; Hu C; Xu P; Ma L; Liu L; Sun J; Liu Y; Yang H; Pan F; Hu J; Cao C; Cheng K; Gao D; Lyu Y; Qin W
    Hum Vaccin Immunother; 2023 Dec; 19(1):2194189. PubMed ID: 36998173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death.
    Huang Z; Xu S; Liu J; Wu L; Qiu J; Wang N; Ren J; Li Z; Guo X; Tao F; Chen J; Lu D; Sun X; Wang W
    BMC Med; 2022 Oct; 20(1):400. PubMed ID: 36266697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis.
    Xu S; Li J; Wang H; Wang F; Yin Z; Wang Z
    BMC Med; 2023 Apr; 21(1):160. PubMed ID: 37106390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of inactivated COVID-19 vaccines against SARS-CoV-2 infections among healthcare personnel in Pakistan: a test-negative case-control study.
    Khan UI; Niaz M; Azam I; Hasan Z; Hassan I; Mahmood SF; Ali A
    BMJ Open; 2023 Jun; 13(6):e071789. PubMed ID: 37369396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Inactivated Vaccine against SARS-CoV-2 Delta Variant Infection in Xiamen, China-A Test-Negative Case-Control Study.
    He T; Wang M; Mi H; Xu L; Lu W; Ouyang X; Guo Z; Su C
    Vaccines (Basel); 2023 Feb; 11(3):. PubMed ID: 36992116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of mRNA BNT162b2 COVID-19 vaccine against SARS-CoV-2 Delta variant among elderly residents from a long-term care facility, South of France, May 2021.
    Sánchez Ruiz MA; Adonias G; Robaglia-Schlupp A; Rapilly F; Chabert M; Ramalli L; Reilhes O; Bruel C; Malfait P; Chaud P
    Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2586-2591. PubMed ID: 35442474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco.
    Belayachi J; Obtel M; Mhayi A; Razine R; Abouqal R
    PLoS One; 2022; 17(12):e0278546. PubMed ID: 36477077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 during Delta variant surge: a preliminary assessment from a case-control study in St. Petersburg, Russia.
    Barchuk A; Bulina A; Cherkashin M; Berezina N; Rakova T; Kuplevatskaya D; Stanevich O; Skougarevskiy D; Okhotin A
    BMC Public Health; 2022 Sep; 22(1):1803. PubMed ID: 36138385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Ferdinands JM; Rao S; Dixon BE; Mitchell PK; DeSilva MB; Irving SA; Lewis N; Natarajan K; Stenehjem E; Grannis SJ; Han J; McEvoy C; Ong TC; Naleway AL; Reese SE; Embi PJ; Dascomb K; Klein NP; Griggs EP; Konatham D; Kharbanda AB; Yang DH; Fadel WF; Grisel N; Goddard K; Patel P; Liao IC; Birch R; Valvi NR; Reynolds S; Arndorfer J; Zerbo O; Dickerson M; Murthy K; Williams J; Bozio CH; Blanton L; Verani JR; Schrag SJ; Dalton AF; Wondimu MH; Link-Gelles R; Azziz-Baumgartner E; Barron MA; Gaglani M; Thompson MG; Fireman B
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):255-263. PubMed ID: 35176007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study.
    Desai D; Khan AR; Soneja M; Mittal A; Naik S; Kodan P; Mandal A; Maher GT; Kumar R; Agarwal A; Gowda NR; H V; Kumar P; Pandey S; Pandey RM; Kumar A; Ray A; Jorwal P; Nischal N; Choudhary A; Brijwal M; Madan K; Lodha R; Sinha S; Dar L; Wig N; Guleria R
    Lancet Infect Dis; 2022 Mar; 22(3):349-356. PubMed ID: 34826383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine effectiveness against referral to hospital after SARS-CoV-2 infection in St. Petersburg, Russia, during the Delta variant surge: a test-negative case-control study.
    Barchuk A; Cherkashin M; Bulina A; Berezina N; Rakova T; Kuplevatskaya D; Stanevich O; Skougarevskiy D; Okhotin A
    BMC Med; 2022 Sep; 20(1):312. PubMed ID: 36123681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China : A Cohort Study.
    Kang M; Yi Y; Li Y; Sun L; Deng A; Hu T; Zhang J; Liu J; Cheng M; Xie S; Luo M; Jiang J; Jiang Y; Tang S; He J
    Ann Intern Med; 2022 Apr; 175(4):533-540. PubMed ID: 35099990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world vaccine effectiveness of mRNA vaccines for SARS-CoV-2; a test-negative case-control study in a medium-sized clinic.
    Aoshima M; Ohfuji S
    Hum Vaccin Immunother; 2022 Dec; 18(7):2147353. PubMed ID: 36459056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study.
    Bruxvoort KJ; Sy LS; Qian L; Ackerson BK; Luo Y; Lee GS; Tian Y; Florea A; Aragones M; Tubert JE; Takhar HS; Ku JH; Paila YD; Talarico CA; Tseng HF
    BMJ; 2021 Dec; 375():e068848. PubMed ID: 34911691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of inactivated COVID-19 vaccines in preventing COVID-19-related hospitalization during the Omicron BF.7-predominant epidemic wave in Beijing, China: a cohort study.
    Zhao D; Sun Y; Li J; Li X; Ma Y; Cao Z; Zhang J; Ma J; Li J; Wang Q; Suo L; Zhang D; Yang P
    BMC Infect Dis; 2024 Sep; 24(1):991. PubMed ID: 39289630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination.
    Yang W; Shaman J
    medRxiv; 2021 Nov; ():. PubMed ID: 34845460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS).
    Maeda H; Saito N; Igarashi A; Ishida M; Suami K; Yagiuchi A; Kimura Y; Komino M; Arai H; Morikawa T; Motohashi I; Miyazawa R; Moriyama T; Kamura H; Terada M; Kuwamitsu O; Hayakawa T; Sando E; Ohara Y; Teshigahara O; Suzuki M; Morimoto K
    Clin Infect Dis; 2022 Nov; 75(11):1971-1979. PubMed ID: 35438137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.